Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib + Olaparib in PARP-resistant Ovarian Cancer
NCT02681237Completed
- Sponsor
- University Health Network
- Start
- Apr 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cediranib in ovarian cancer, sponsored by University Health Network. Primary endpoints: Objective Response Rate at 8 weeks and Progression-Free Survival Rate at 16 weeks. Started Apr 2016; status: completed.
02
Drugs
cediranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02681237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02681237.